Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...